SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) today announced financial results for the second quarter ended June 30, 2007.
Optimer reported a net loss allocable to common stockholders for the second quarter of 2007 of $8.1 million, or $0.35 per common share, as compared to a net loss of $3.8 million, or $1.53 per common share, for the comparable quarter in 2006. The increase of $4.3 million was due primarily to an increase in clinical development expenses of $3.4 million for the advancement of Optimer’s OPT-80 and Prulifloxacin clinical trials. For the six months ended June 30, 2007, Optimer reported a net loss allocable to common stockholders of $32.6 million, or $1.75 per share, as compared to a net loss of $5.9 million, or $2.37 per share, for the comparable six month period in 2006. The increase of $26.7 million was due primarily to a $20.0 million payment to Par Pharmaceutical, Inc., or Par, to reacquire the North American rights to OPT-80.
